Previous efforts have been taken to characterize other secreted factors in FD, including the demonstration of lesional FGF23 excess [12] and investigations of IL-6 that led to an unsuccessful attempt to treat FD patients with the IL6R-inhibiting drug tocilizumab [13,14,15]. Here, IL6R is linked to Fabry disease.